|
US7605238B2
(en)
*
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
KR100996759B1
(ko)
*
|
1999-08-24 |
2010-11-25 |
메다렉스, 인코포레이티드 |
인간 씨티엘에이-4 항체 및 그의 용도
|
|
KR100951067B1
(ko)
|
2000-02-10 |
2010-04-07 |
아보트 러보러터리즈 |
사람 인터류킨-18에 결합하는 항체 및 이를 제조하고사용하는 방법
|
|
JP4986370B2
(ja)
|
2000-12-22 |
2012-07-25 |
マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ |
Ｒｇｍおよびそのモジュレーターの用途
|
|
HUP0302525A2
(hu)
|
2001-01-05 |
2003-10-28 |
Abgenix, Inc. |
Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok
|
|
TR200301846T2
(tr)
|
2001-04-26 |
2006-10-26 |
Biogen Idec Ma Inc. |
Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
|
|
EP1463522A4
(en)
|
2001-05-16 |
2005-04-13 |
Einstein Coll Med |
HUMAN ANTIPNEUMOKOKKEN ANTIBODIES OF NON-THUMBAN ANIMALS
|
|
IL149701A0
(en)
*
|
2001-05-23 |
2002-11-10 |
Pfizer Prod Inc |
Use of anti-ctla-4 antibodies
|
|
ATE464068T1
(de)
*
|
2001-06-26 |
2010-04-15 |
Amgen Fremont Inc |
Antikörper gegen opgl
|
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
CN1326879C
(zh)
|
2002-03-29 |
2007-07-18 |
先灵公司 |
人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
|
|
CA2481207C
(en)
*
|
2002-04-12 |
2015-06-30 |
Medarex, Inc. |
Methods of treatment using ctla-4 antibodies
|
|
EP1549678A4
(en)
*
|
2002-09-30 |
2006-01-18 |
Pfizer Prod Inc |
HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
US7465446B2
(en)
|
2003-05-30 |
2008-12-16 |
Medarex, Inc. |
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
CA2535859A1
(en)
*
|
2003-08-14 |
2005-03-03 |
Dyax Corp. |
Endotheliase-2 ligands
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
|
AR047372A1
(es)
|
2004-01-09 |
2006-01-18 |
Pfizer |
Anticuerpos contra madcam
|
|
JP2007530526A
(ja)
*
|
2004-03-26 |
2007-11-01 |
ファイザー・プロダクツ・インク |
抗ｃｔｌａ−４抗体の使用
|
|
US7494779B2
(en)
|
2004-06-14 |
2009-02-24 |
Li-Te Chin |
Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
|
|
CN1997670B
(zh)
|
2004-07-01 |
2014-04-30 |
诺和诺德公司 |
人类抗-kir抗体
|
|
MX2007000610A
(es)
|
2004-07-16 |
2007-03-07 |
Pfizer Prod Inc |
Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
|
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
|
AU2014240252B2
(en)
*
|
2005-03-08 |
2016-10-06 |
Pfizer Products Inc |
Anti-CTLA-4 Antibody Compositions
|
|
TW200719913A
(en)
*
|
2005-03-08 |
2007-06-01 |
Pharmacia & Upjohn Co Llc |
Anti-madcam antibody compositions
|
|
AU2012200203B2
(en)
*
|
2005-03-08 |
2014-07-03 |
Pfizer Products Inc. |
Anti-CTLA-4 Antibody Compositions
|
|
JP2006265155A
(ja)
*
|
2005-03-23 |
2006-10-05 |
Link Genomics Kk |
癌の免疫療法
|
|
AU2006227879A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Pfizer Products Inc. |
Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
|
|
CA2602777C
(en)
|
2005-03-25 |
2018-12-11 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
AR053067A1
(es)
|
2005-04-25 |
2007-04-18 |
Pfizer |
Anticuerpos contra miostatina
|
|
EP1877444A2
(en)
|
2005-04-26 |
2008-01-16 |
Pfizer, Inc. |
P-cadherin antibodies
|
|
US20090041783A1
(en)
|
2005-04-28 |
2009-02-12 |
Mochida Pharmaceutical Co., Ltd. |
Anti-platelet membrane glycoprotein vi monoclonal antibody
|
|
JP5224707B2
(ja)
*
|
2005-04-28 |
2013-07-03 |
持田製薬株式会社 |
抗血小板膜糖蛋白質ｖｉモノクローナル抗体
|
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
SI2397156T1
(sl)
|
2005-06-08 |
2017-06-30 |
Dana-Farber Cancer Institute, Inc. |
Metode in sestavki za zdravljenje trdovratnih okužb in raka z inhibiranjem polipeptida za apoptozo 1 (PD-1)
|
|
EA200800268A1
(ru)
*
|
2005-07-07 |
2008-06-30 |
Коли Фармасьютикал Груп, Инк. |
КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
|
|
CN100443503C
(zh)
*
|
2005-07-18 |
2008-12-17 |
四川大学华西医院 |
人源化ctla-4单链抗体与人穿孔素通道形成肽p34的重组免疫毒素
|
|
JP5364870B2
(ja)
|
2005-08-19 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP2500359A3
(en)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
SI2960253T1
(sl)
|
2005-09-07 |
2018-10-30 |
Amgen Fremont Inc. |
Človeška monoklonska protitelesa proti aktivin receptorski kinazi-1
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
|
WO2007056540A2
(en)
|
2005-11-08 |
2007-05-18 |
Medarex, Inc. |
Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
|
|
PT1954718E
(pt)
|
2005-11-30 |
2014-12-16 |
Abbvie Inc |
Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
|
|
WO2007064972A2
(en)
|
2005-11-30 |
2007-06-07 |
Abbott Laboratories |
Monoclonal antibodies against amyloid beta protein and uses thereof
|
|
US8110194B2
(en)
|
2005-12-07 |
2012-02-07 |
Medarex, Inc. |
CTLA-4 antibody dosage escalation regimens
|
|
EP1997887B1
(en)
|
2006-03-03 |
2013-09-04 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of cell surface functional molecule
|
|
JP6092497B2
(ja)
|
2006-03-30 |
2017-03-08 |
ユニバーシティー オブ カリフォルニア |
抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
|
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
|
BRPI0709481A2
(pt)
|
2006-04-07 |
2011-07-19 |
Government Of The Us Secretary Dept Of Health And Human Services |
anticorpo monoclonal isolado, anticorpo monoclonal humano isolado, composição farmacêutica, anticorpo anti-igf-i e anti-igf-ii recombinante isolado ou fragmento de ligação ao antìgeno do mesmo, método para detectar o fator i e o fator ii de crescimento insulina humana em uma amostra, método para dectetar o fator i de crescimento insulina humana em uma amostra, ácido nucléico isolado, célula recombinante , célula hospedeira ,método para preparar um anticorpo, método para preparar um anticorpo, método para tratar uma doença neoplásica em um indivìduo mamìfero, método para diagnosticar doença neoplásica em um indivìduo mamìfero e método para classificar um composto candidato a fármaco
|
|
RU2009107494A
(ru)
|
2006-08-04 |
2010-09-10 |
Астразенека Аб (Se) |
АНТИТЕЛА К ErbB2
|
|
CA2662701C
(en)
|
2006-09-08 |
2015-12-08 |
Abbott Laboratories |
Interleukin-13 binding proteins
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
|
US20090081237A1
(en)
|
2007-03-12 |
2009-03-26 |
Dana-Farber Cancer Institute |
Prognostic, diagnostic, and cancer therapeutic uses of FANCI and FANCI modulating agents
|
|
RU2009140313A
(ru)
|
2007-04-02 |
2011-05-10 |
Эмджен Фримонт Инк. (Us) |
АНТИТЕЛА ПРОТИВ IgE
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
KR101666228B1
(ko)
|
2007-09-28 |
2016-10-13 |
인트렉손 코포레이션 |
생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
|
|
CN101998965B
(zh)
|
2007-11-01 |
2014-03-12 |
安斯泰来制药有限公司 |
免疫抑制性多肽与核酸
|
|
CA2949772A1
(en)
|
2007-12-14 |
2009-06-25 |
Pfizer Inc. |
Binding molecules to the human ox40 receptor
|
|
JP2011509299A
(ja)
|
2008-01-08 |
2011-03-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
増殖性疾患治療のための、抗ｃｔｌａ−４抗体とチューブリン調節剤との組み合わせ
|
|
US8263073B2
(en)
|
2008-02-04 |
2012-09-11 |
Medarex, Inc. |
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
|
EP2899209A1
(en)
|
2008-04-29 |
2015-07-29 |
Abbvie Inc. |
Dual Variable Domain Immunoglobulins and uses thereof
|
|
MX2010012142A
(es)
|
2008-05-09 |
2011-04-05 |
Abbott Gmbh & Co Kg |
Anticuerpos para receptor de productos finales de glucacion avanzada (rage) y usos de los mismos.
|
|
KR20110016958A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
UY31861A
(es)
|
2008-06-03 |
2010-01-05 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
|
US8822645B2
(en)
|
2008-07-08 |
2014-09-02 |
Abbvie Inc. |
Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
|
|
EP2310049A4
(en)
|
2008-07-08 |
2013-06-26 |
Abbvie Inc |
PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF
|
|
US8119129B2
(en)
|
2008-08-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP5685535B2
(ja)
|
2008-08-18 |
2015-03-18 |
ファイザー インコーポレイティッド |
Ｃｃｒ２に対する抗体
|
|
KR101012267B1
(ko)
*
|
2008-08-29 |
2011-02-08 |
주식회사 세이프로드 |
파손이 방지되는 차선규제봉 및 차선규제봉 시공방법
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
PT2387627E
(pt)
|
2009-01-15 |
2016-06-03 |
Adaptive Biotechnologies Corp |
Determinação do perfil de imunidade adaptativa e métodos de geração de anticorpos monoclonais
|
|
NZ594514A
(en)
|
2009-03-05 |
2013-06-28 |
Abbott Lab |
Interleukin-17 BINDING PROTEINS
|
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
|
ES2768990T3
(es)
|
2009-07-20 |
2020-06-24 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
|
|
US8623358B2
(en)
|
2009-08-29 |
2014-01-07 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
|
AU2010308030B2
(en)
|
2009-10-12 |
2014-05-29 |
Pfizer Inc. |
Cancer treatment
|
|
CN102666875A
(zh)
|
2009-10-15 |
2012-09-12 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
|
AU2010329955A1
(en)
|
2009-12-08 |
2012-05-24 |
Abbott Gmbh & Co. Kg |
Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration
|
|
CN105037543B
(zh)
|
2010-03-02 |
2020-11-03 |
Abbvie 公司 |
治疗性dll4结合蛋白
|
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
|
TWI615405B
(zh)
|
2010-05-14 |
2018-02-21 |
艾伯維有限公司 |
Ｉｌ-１結合蛋白
|
|
EP2571577A1
(en)
|
2010-05-17 |
2013-03-27 |
Bristol-Myers Squibb Company |
Improved immunotherapeutic dosing regimens and combinations thereof
|
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
|
TW201206473A
(en)
|
2010-08-03 |
2012-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CA2808187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbvie Inc. |
Amyloid-beta binding proteins
|
|
HUE058226T2
(hu)
|
2010-08-19 |
2022-07-28 |
Zoetis Belgium S A |
NGF elleni antitestek és alkalmazásuk
|
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
|
WO2012072806A1
(en)
*
|
2010-12-02 |
2012-06-07 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for ctla-4
|
|
DK2651975T3
(en)
|
2010-12-14 |
2017-10-30 |
Nat Univ Singapore |
HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY OF DENGUE VIRUS SEROTYPE-1E PROTEIN AND APPLICATIONS THEREOF
|
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Ｉｌ－１結合蛋白
|
|
MY163368A
(en)
|
2010-12-21 |
2017-09-15 |
Abbvie Inc |
Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
|
TWI687441B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
|
SG10201505454SA
(en)
|
2011-07-13 |
2015-09-29 |
Abbvie Inc |
Methods and compositions for treating asthma using anti-il-13 antibodies
|
|
WO2013013029A1
(en)
|
2011-07-19 |
2013-01-24 |
The Board Of Trustees Of The University Of Illinois |
Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
|
|
EP2750768B1
(en)
|
2011-08-30 |
2018-10-03 |
Astex Pharmaceuticals, Inc. |
Decitabine derivative formulations
|
|
SG11201401791WA
(en)
|
2011-10-24 |
2014-08-28 |
Abbvie Inc |
Immunobinders directed against sclerostin
|
|
RS20140203A1
(en)
|
2011-10-24 |
2014-10-31 |
Abbvie Inc. |
IMMUNOVELING PROTEINS AGAINST TNF
|
|
BR112014011115A2
(pt)
|
2011-11-08 |
2017-06-13 |
Pfizer |
métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
|
|
CN104136462B
(zh)
|
2011-12-14 |
2017-06-09 |
艾伯维德国有限责任两合公司 |
用于诊断和治疗铁相关病症的组合物和方法
|
|
EP2791173B1
(en)
|
2011-12-14 |
2020-07-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
|
EP2807192B1
(en)
|
2012-01-27 |
2018-04-18 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
|
US20150110779A1
(en)
|
2012-03-15 |
2015-04-23 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
|
US9534059B2
(en)
|
2012-04-13 |
2017-01-03 |
Children's Medical Center Corporation |
TIKI inhibitors
|
|
MX376234B
(es)
|
2012-05-04 |
2025-03-07 |
Pfizer |
Anticuerpo anti-ctla-4 como modulador inmune.
|
|
WO2013169971A1
(en)
|
2012-05-10 |
2013-11-14 |
Bristol-Myers Squibb Company |
Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
|
|
IL289750B1
(en)
|
2012-05-15 |
2025-06-01 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
CN104364264B
(zh)
|
2012-06-06 |
2018-07-24 |
硕腾服务有限责任公司 |
犬源化抗ngf抗体和其方法
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
US9670276B2
(en)
|
2012-07-12 |
2017-06-06 |
Abbvie Inc. |
IL-1 binding proteins
|
|
US8968742B2
(en)
*
|
2012-08-23 |
2015-03-03 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
|
|
AU2013337775B2
(en)
|
2012-11-01 |
2017-03-30 |
Abbvie Inc. |
Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
|
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
|
DK2961388T3
(da)
|
2013-03-01 |
2019-07-08 |
Astex Pharmaceuticals Inc |
Kombinationer af lægemidler
|
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ |
改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
|
|
WO2014153056A2
(en)
|
2013-03-14 |
2014-09-25 |
Parkash Gill |
Cancer treatment using antibodies that bing cell surface grp78
|
|
CN105378099B
(zh)
|
2013-03-14 |
2021-05-11 |
雅培制药有限公司 |
Hcv核心脂质结合结构域单克隆抗体
|
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
|
EP2970459A2
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Dual specific binding proteins directed against il-1beta and il-17
|
|
CA2914566A1
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
|
JP6649254B2
(ja)
|
2013-08-08 |
2020-02-19 |
サイチューン ファーマ |
ＩＬ−１５及びＩＬ−１５Ｒαスシドメインに基づくモジュロカイン
|
|
EP3030262B1
(en)
|
2013-08-08 |
2019-10-09 |
Cytune Pharma |
Combined pharmaceutical composition
|
|
HUE044730T2
(hu)
|
2013-09-20 |
2019-11-28 |
Bristol Myers Squibb Co |
Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
|
|
WO2015063647A1
(en)
|
2013-11-01 |
2015-05-07 |
Pfizer Inc. |
Vectors for expression of prostate-associated antigens
|
|
MX2016005925A
(es)
|
2013-11-05 |
2016-11-28 |
Cognate Bioservices Inc |
Combinaciones de inhibidores de punto de regulacion y terapeuticos para tratar el cancer.
|
|
US20160264670A1
(en)
|
2013-11-06 |
2016-09-15 |
Bristol-Myers Squibb Company |
Immunotherapeutic dosing regimens and combinations thereof
|
|
WO2015104406A2
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Ag |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
NZ764826A
(en)
|
2014-05-28 |
2024-09-27 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
|
EP3151921B1
(en)
|
2014-06-06 |
2019-08-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
|
CA2944085C
(en)
|
2014-09-16 |
2018-04-10 |
Ease Charm Limited |
Anti-egfr antibody and uses of same
|
|
MX391478B
(es)
|
2014-10-10 |
2025-03-21 |
Idera Pharmaceuticals Inc |
Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
|
|
NZ746680A
(en)
|
2014-10-14 |
2020-07-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
CN107074976B
(zh)
*
|
2014-11-04 |
2020-10-09 |
北京韩美药品有限公司 |
同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白
|
|
CN105597090B
(zh)
*
|
2014-11-14 |
2022-08-23 |
中国科学院上海营养与健康研究所 |
一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
|
|
ES2826566T3
(es)
|
2014-11-21 |
2021-05-18 |
Bristol Myers Squibb Co |
Anticuerpos que comprenden regiones constantes pesadas modificadas
|
|
SMT202000413T1
(it)
|
2014-11-21 |
2020-09-10 |
Bristol Myers Squibb Co |
Anticorpi nei confronti di cd73 e loro usi
|
|
CN107249632A
(zh)
|
2014-12-04 |
2017-10-13 |
百时美施贵宝公司 |
用于治疗癌症(骨髓瘤)的抗cs1与抗pd‑1抗体的组合
|
|
CN104387453A
(zh)
*
|
2014-12-08 |
2015-03-04 |
深圳市同康生物医药有限公司 |
树突状细胞靶向肽及编码基因及应用
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
EA039219B1
(ru)
|
2014-12-23 |
2021-12-20 |
Бристол-Майерс Сквибб Компани |
Антитела к tigit
|
|
PT3240801T
(pt)
|
2014-12-31 |
2021-02-18 |
Checkmate Pharmaceuticals Inc |
Imunoterapia antitumoral combinada
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
AR103675A1
(es)
*
|
2015-02-13 |
2017-05-24 |
Sorrento Therapeutics Inc |
Anticuerpos anti-ctla4 terapéuticos
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
WO2016154629A1
(en)
|
2015-03-26 |
2016-09-29 |
Woman & Infants' Hospital Of Rhode Island |
Therapy for malignant disease
|
|
TWI738646B
(zh)
|
2015-04-07 |
2021-09-11 |
日商賽多利克公司 |
醫藥組成物
|
|
KR20230174291A
(ko)
|
2015-05-06 |
2023-12-27 |
스니프르 테크놀로지스 리미티드 |
미생물 개체군 변경 및 미생물군 변형
|
|
CN107921126A
(zh)
|
2015-05-22 |
2018-04-17 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
|
RS63897B1
(sr)
|
2015-05-29 |
2023-02-28 |
Bristol Myers Squibb Co |
Antitela protiv ox40 i njihova primena
|
|
LT3303395T
(lt)
|
2015-05-29 |
2020-02-25 |
Abbvie Inc. |
Anti-cd40 antikūnai ir jų panaudojimas
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
HUE056491T2
(hu)
|
2015-06-29 |
2022-02-28 |
Bristol Myers Squibb Co |
Immunterápiás adagolási rendszerek, amelyek tartalmaznak pomalidomid-et és anti-CS1-antitestet rák kezelésére
|
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
|
MX2018000016A
(es)
|
2015-07-02 |
2019-01-31 |
Otsuka Pharma Co Ltd |
Composiciones farmaceuticas liofilizadas.
|
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
|
HK1248115A1
(zh)
|
2015-07-16 |
2018-10-12 |
Bioxcel Therapeutics, Inc. |
一種使用免疫調節治療癌症的新穎方法
|
|
WO2017021913A1
(en)
|
2015-08-04 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments and uses and methods thereof
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
JP2018531625A
(ja)
|
2015-09-11 |
2018-11-01 |
ナセント バイオテック インコーポレイテッド |
脳への向上した薬物送達の方法
|
|
LT3370733T
(lt)
|
2015-11-02 |
2021-10-25 |
Board Of Regents, The University Of Texas System |
Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai
|
|
JP2019503985A
(ja)
|
2015-11-03 |
2019-02-14 |
グリコミメティクス， インコーポレイテッド |
モノクローナル抗体、造血幹細胞の産生のための方法および組成物、ならびにそれらを使用する方法
|
|
CN108884159A
(zh)
|
2015-11-07 |
2018-11-23 |
茂体外尔公司 |
用于癌症治疗的包含肿瘤抑制基因治疗和免疫检查点阻断的组合物
|
|
AU2016356780A1
(en)
|
2015-11-19 |
2018-06-28 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
TWI717432B
(zh)
|
2015-12-02 |
2021-02-01 |
美商艾吉納斯公司 |
抗體和使用彼之方法
|
|
KR102424513B1
(ko)
|
2015-12-14 |
2022-07-25 |
마크로제닉스, 인크. |
Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
|
|
WO2017120612A1
(en)
|
2016-01-10 |
2017-07-13 |
Modernatx, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
|
JP2019514844A
(ja)
|
2016-03-04 |
2019-06-06 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｃｄ７３抗体を用いた併用療法
|
|
WO2017160599A1
(en)
|
2016-03-14 |
2017-09-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cd300b antagonists to treat sepsis and septic shock
|
|
EP3429693B1
(en)
|
2016-03-15 |
2023-08-23 |
Mersana Therapeutics, Inc. |
Napi2b-targeted antibody-drug conjugates and methods of use thereof
|
|
LT3429618T
(lt)
|
2016-03-16 |
2024-05-10 |
Amal Therapeutics Sa |
Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje
|
|
US11046782B2
(en)
|
2016-03-30 |
2021-06-29 |
Musc Foundation For Research Development |
Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
|
|
WO2017173334A1
(en)
|
2016-04-01 |
2017-10-05 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
|
MX393066B
(es)
|
2016-04-18 |
2025-03-24 |
Celldex Therapeutics Inc |
Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
|
|
CA3022377A1
(en)
|
2016-04-29 |
2017-11-02 |
Board Of Regents, The University Of Texas System |
Targeted measure of transcriptional activity related to hormone receptors
|
|
US20190298824A1
(en)
|
2016-05-04 |
2019-10-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
|
EP3458092A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Mrna combination therapy for the treatment of cancer
|
|
CN109641044A
(zh)
|
2016-05-30 |
2019-04-16 |
吉奥瓦科斯公司 |
用于产生对乙型肝炎病毒的免疫应答的组合物和方法
|
|
US10994033B2
(en)
|
2016-06-01 |
2021-05-04 |
Bristol-Myers Squibb Company |
Imaging methods using 18F-radiolabeled biologics
|
|
GB201609811D0
(en)
|
2016-06-05 |
2016-07-20 |
Snipr Technologies Ltd |
Methods, cells, systems, arrays, RNA and kits
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
CA3029426A1
(en)
|
2016-06-30 |
2018-01-04 |
Oncorus, Inc. |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
CN117683135A
(zh)
|
2016-07-14 |
2024-03-12 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
NL2017270B1
(en)
*
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
|
WO2018025221A1
(en)
|
2016-08-04 |
2018-02-08 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-icos and anti-pd-1 antibody combination therapy
|
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
|
DK3515476T3
(da)
|
2016-09-21 |
2024-09-02 |
Amal Therapeutics Sa |
Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer
|
|
JP7542946B2
(ja)
|
2016-09-27 |
2024-09-02 |
ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム |
マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
|
|
WO2018067474A1
(en)
|
2016-10-03 |
2018-04-12 |
Abbott Laboratories |
Improved methods of assessing gfap status in patient samples
|
|
JP6976322B2
(ja)
*
|
2016-10-10 |
2021-12-08 |
クラウン バイオサイエンス，インコーポレイテッド（タイツァン） |
新規抗ｃｔｌａ４抗体
|
|
CN109982711A
(zh)
|
2016-10-11 |
2019-07-05 |
Cytlimic公司 |
药物
|
|
MX386249B
(es)
|
2016-10-12 |
2025-03-18 |
Univ Texas |
Terapia tusc2 para usarse en el tratamiento de cáncer.
|
|
CN110099925A
(zh)
|
2016-10-28 |
2019-08-06 |
百时美施贵宝公司 |
使用抗pd-1抗体治疗尿道上皮癌的方法
|
|
WO2018089293A2
(en)
*
|
2016-11-08 |
2018-05-17 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
|
CA3043356A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
WO2018089628A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CU20190051A7
(es)
|
2016-11-17 |
2020-01-03 |
Univ Texas |
Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
IL300095A
(en)
|
2016-11-23 |
2023-03-01 |
Translational Drug Dev Llc |
Benzamide and tumor necrosis factor receptor superfamily agonist compositions and uses thereof
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
BR112019011370A2
(pt)
|
2016-12-01 |
2019-10-15 |
Glaxosmithkline Ip Dev Ltd |
terapia de combinação
|
|
CN110234342A
(zh)
|
2016-12-01 |
2019-09-13 |
葛兰素史密斯克莱知识产权发展有限公司 |
组合疗法
|
|
WO2018111902A1
(en)
|
2016-12-12 |
2018-06-21 |
Multivir Inc. |
Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
|
|
AU2017377233B2
(en)
|
2016-12-12 |
2024-12-19 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156250A1
(en)
*
|
2017-02-21 |
2018-08-30 |
Remd Biotherapeutics, Inc. |
Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
|
|
US11693007B2
(en)
|
2017-02-24 |
2023-07-04 |
Board Of Regents, The University Of Texas System |
Assay for detection of early stage pancreatic cancer
|
|
EP3366703B1
(en)
|
2017-02-28 |
2019-04-03 |
Ralf Kleef |
Immune checkpoint therapy with hyperthermia
|
|
US20180271996A1
(en)
|
2017-02-28 |
2018-09-27 |
Mersana Therapeutics, Inc. |
Combination therapies of her2-targeted antibody-drug conjugates
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
|
US20210101980A1
(en)
|
2017-03-31 |
2021-04-08 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
WO2018191531A1
(en)
|
2017-04-15 |
2018-10-18 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
CN110603449A
(zh)
|
2017-04-28 |
2019-12-20 |
雅培实验室 |
用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
|
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
|
CN116478289A
(zh)
*
|
2017-05-19 |
2023-07-25 |
上海药明生物技术有限公司 |
一种新的ctla-4单克隆抗体
|
|
CA3060618A1
(en)
|
2017-05-19 |
2018-11-22 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
|
|
KR20240149979A
(ko)
|
2017-05-25 |
2024-10-15 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
|
HUE065242T2
(hu)
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
|
CN110691795A
(zh)
|
2017-05-30 |
2020-01-14 |
百时美施贵宝公司 |
包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物
|
|
WO2018222722A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
|
US10849548B2
(en)
|
2017-05-30 |
2020-12-01 |
Abbott Laboratories |
Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
|
|
KR20200015717A
(ko)
|
2017-06-09 |
2020-02-12 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
|
|
US11169159B2
(en)
|
2017-07-03 |
2021-11-09 |
Abbott Laboratories |
Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
|
|
AU2018300189B2
(en)
|
2017-07-14 |
2025-05-15 |
Pfizer, Inc. |
Antibodies to MAdCAM
|
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
TWI799432B
(zh)
*
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
CA3071755A1
(en)
|
2017-08-03 |
2019-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
JP2020536114A
(ja)
|
2017-10-06 |
2020-12-10 |
ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー |
癌の処置および予防のためｃｔｌａ−４を標的とするｄｎａモノクローナル抗体
|
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
|
AU2018346957B2
(en)
|
2017-10-12 |
2024-08-01 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
WO2019075468A1
(en)
|
2017-10-15 |
2019-04-18 |
Bristol-Myers Squibb Company |
TUMOR TREATMENT METHODS
|
|
US11603410B2
(en)
|
2017-11-01 |
2023-03-14 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
CA3079999A1
(en)
|
2017-11-07 |
2019-05-16 |
The Board Of Regents Of The University Of Texas System |
Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
|
|
EP3717021A1
(en)
|
2017-11-27 |
2020-10-07 |
Mersana Therapeutics, Inc. |
Pyrrolobenzodiazepine antibody conjugates
|
|
CN108003238B
(zh)
*
|
2017-11-30 |
2021-02-02 |
常州费洛斯药业科技有限公司 |
一种能特异识别ctla-4的全人源单克隆抗体或抗体片段及其方法和用途
|
|
CA3067057A1
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
|
CN110892266A
(zh)
|
2017-12-09 |
2020-03-17 |
雅培实验室 |
使用gfap和uch-l1的组合辅助诊断和评价人类受试者中创伤性脑损伤的方法
|
|
CA3085861C
(en)
*
|
2017-12-20 |
2023-09-26 |
Harbour Biomed (Shanghai) Co., Ltd |
Antibodies binding ctla-4 and uses thereof
|
|
CN111757757A
(zh)
|
2017-12-21 |
2020-10-09 |
梅尔莎纳医疗公司 |
吡咯并苯并二氮呯抗体共轭物
|
|
CN111788227B
(zh)
|
2017-12-27 |
2025-02-25 |
百时美施贵宝公司 |
抗cd40抗体及其用途
|
|
WO2019133847A1
(en)
|
2017-12-29 |
2019-07-04 |
Oncorus, Inc. |
Oncolytic viral delivery of therapeutic polypeptides
|
|
WO2019140229A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
CN111629731A
(zh)
|
2018-01-22 |
2020-09-04 |
百时美施贵宝公司 |
治疗癌症的组合物和方法
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
|
CN112218658A
(zh)
|
2018-03-12 |
2021-01-12 |
国家健康科学研究所 |
热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
|
|
WO2019177690A1
(en)
|
2018-03-12 |
2019-09-19 |
Zoetis Services Llc |
Anti-ngf antibodies and methods thereof
|
|
EP3768721A4
(en)
*
|
2018-03-19 |
2021-12-29 |
Wuxi Biologics Ireland Limited. |
Novel anti-ctla-4 antibody polypeptide
|
|
CN112020510B
(zh)
|
2018-03-19 |
2024-10-11 |
茂体外尔公司 |
包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
|
|
US12173069B2
(en)
|
2018-03-21 |
2024-12-24 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic pH
|
|
BR112020018539A2
(pt)
|
2018-03-23 |
2020-12-29 |
Bristol-Myers Squibb Company |
Anticorpos contra mica e/ou micb e usos dos mesmos
|
|
EP3773685A1
(en)
|
2018-03-25 |
2021-02-17 |
SNIPR Biome ApS. |
Treating & preventing microbial infections
|
|
US10760075B2
(en)
|
2018-04-30 |
2020-09-01 |
Snipr Biome Aps |
Treating and preventing microbial infections
|
|
RU2020134932A
(ru)
|
2018-03-27 |
2022-04-27 |
Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем |
Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2
|
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
SG11202009647VA
(en)
|
2018-04-09 |
2020-10-29 |
Checkmate Pharmaceuticals |
Packaging oligonucleotides into virus-like particles
|
|
MX2020010912A
(es)
|
2018-04-18 |
2021-01-29 |
Xencor Inc |
Proteínas il-15/il-15ra de fusión a fc heterodiméricas y usos de las mismas.
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
BR112020021539A2
(pt)
|
2018-04-25 |
2021-01-19 |
Innate Tumor Immunity, Inc. |
Moduladores de nlrp3
|
|
TW202017569A
(zh)
|
2018-05-31 |
2020-05-16 |
美商佩樂敦治療公司 |
用於抑制cd73之組合物及方法
|
|
CN112566643A
(zh)
|
2018-06-12 |
2021-03-26 |
加利福尼亚大学董事会 |
用于治疗癌症的单链双特异性嵌合抗原受体
|
|
MY201995A
(en)
|
2018-07-09 |
2024-03-28 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
|
EP3820902A2
(en)
|
2018-07-11 |
2021-05-19 |
Five Prime Therapeutics, Inc. |
Antibodies binding to vista at acidic ph
|
|
EP3820992A2
(en)
|
2018-07-11 |
2021-05-19 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
MX2021000745A
(es)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Composiciones anti-cd112r y metodos.
|
|
KR20210046022A
(ko)
|
2018-08-16 |
2021-04-27 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
치환된 4-아미노-1H-이미다조[4,5-c]퀴놀린 화합물 및 그의 개선된 제조 방법
|
|
CN113038989A
(zh)
|
2018-08-16 |
2021-06-25 |
先天肿瘤免疫公司 |
咪唑并[4,5-c]喹啉衍生的nlrp3调节剂
|
|
KR102817037B1
(ko)
|
2018-08-16 |
2025-06-04 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제
|
|
EP3617230A1
(en)
|
2018-09-03 |
2020-03-04 |
BioInvent International AB |
Novel antibodies and nucleotide sequences, and uses thereof
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
JP7618950B2
(ja)
|
2018-09-19 |
2025-01-22 |
インサーム （インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル） |
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物
|
|
US12269855B2
(en)
|
2018-09-21 |
2025-04-08 |
Innovent Biologics (Suzhou) Co., Ltd. |
Interleukin-2 and use thereof
|
|
CA3098765A1
(en)
|
2018-09-21 |
2020-03-26 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel interleukin-2 and use thereof
|
|
EP3860578A1
(en)
|
2018-10-01 |
2021-08-11 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
|
TW202035445A
(zh)
|
2018-10-10 |
2020-10-01 |
美商帝洛斯療法股份有限公司 |
抗lap抗體變異體及其用途
|
|
WO2020077276A2
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
EP3870609A1
(en)
|
2018-10-23 |
2021-09-01 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3873534A1
(en)
|
2018-10-29 |
2021-09-08 |
Mersana Therapeutics, Inc. |
Cysteine engineered antibody-drug conjugates with peptide-containing linkers
|
|
CN120594829A
(zh)
|
2018-11-09 |
2025-09-05 |
皮埃里亚生物科学有限责任公司 |
用于测定肿瘤微环境组成的方法和组合物
|
|
AU2019380307A1
(en)
|
2018-11-16 |
2021-07-01 |
Bristol-Myers Squibb Company |
Anti-NKG2A antibodies and uses thereof
|
|
US20220033848A1
(en)
|
2018-11-19 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
A modular, polycistronic vector for car and tcr transduction
|
|
US20220031749A1
(en)
|
2018-11-28 |
2022-02-03 |
Board Of Regents, The University Of Texas System |
Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
|
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
ES2971964T3
(es)
|
2018-11-28 |
2024-06-10 |
Inst Nat Sante Rech Med |
Métodos y kit para someter a ensayo el potencial lítico de células efectoras inmunitarias
|
|
AU2019386830A1
(en)
|
2018-11-29 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
EP3891270A1
(en)
|
2018-12-07 |
2021-10-13 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
US10952996B2
(en)
|
2018-12-11 |
2021-03-23 |
Theravance Biopharma R&D Ip, Llc |
ALK5 inhibitors
|
|
US20220047556A1
(en)
|
2018-12-17 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sulconazole as a furin inhibitor
|
|
AU2019416220A1
(en)
|
2018-12-26 |
2021-07-22 |
Xilio Development, Inc. |
anti-CTLA4 antibodies and methods of use thereof
|
|
KR20210110838A
(ko)
|
2018-12-28 |
2021-09-09 |
트랜스진 에스.에이. |
M2 결함성 폭스바이러스
|
|
CN113286787A
(zh)
|
2019-01-14 |
2021-08-20 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
US12391675B2
(en)
|
2019-01-14 |
2025-08-19 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
EP3911416B1
(en)
|
2019-01-14 |
2024-06-12 |
Innate Tumor Immunity, Inc. |
Substituted quinazolines as nlrp3 modulators, for use in the treatment of cancer
|
|
WO2020150114A1
(en)
|
2019-01-14 |
2020-07-23 |
Innate Tumor Immunity, Inc. |
Heterocyclic nlrp3 modulators, for use in the treatment of cancer
|
|
JP7645185B2
(ja)
|
2019-01-15 |
2025-03-13 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
WO2020182993A1
(en)
|
2019-03-13 |
2020-09-17 |
Etherna Immunotherapies Nv |
Mrna vaccine
|
|
KR20210146348A
(ko)
|
2019-03-28 |
2021-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
JP2022526960A
(ja)
|
2019-03-28 |
2022-05-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
|
WO2020201362A2
(en)
|
2019-04-02 |
2020-10-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
WO2020206169A1
(en)
|
2019-04-02 |
2020-10-08 |
Kupper Thomas S |
Methods for identifying progression of a primary melanoma
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
WO2020212484A1
(en)
|
2019-04-17 |
2020-10-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
AU2020268199B2
(en)
|
2019-05-09 |
2025-08-21 |
FUJIFILM Cellular Dynamics, Inc. |
Methods for the production of hepatocytes
|
|
CN114096240A
(zh)
|
2019-05-17 |
2022-02-25 |
癌症预防制药股份有限公司 |
用于治疗家族性腺瘤性息肉病的方法
|
|
JP2022534982A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよびその使用
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
WO2020243570A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
BR112021024438A2
(pt)
|
2019-06-03 |
2022-02-15 |
Univ Chicago |
Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno
|
|
WO2020247973A1
(en)
|
2019-06-03 |
2020-12-10 |
The University Of Chicago |
Methods and compositions for treating cancer with cancer-targeted adjuvants
|
|
US20210038684A1
(en)
|
2019-06-11 |
2021-02-11 |
Alkermes Pharma Ireland Limited |
Compositions and Methods for Cancer Immunotherapy
|
|
MX2021015802A
(es)
|
2019-06-27 |
2022-04-01 |
Etherna Immunotherapies Nv |
Terapia de combinacion.
|
|
BR112021026832A2
(pt)
|
2019-07-02 |
2022-05-10 |
Hutchinson Fred Cancer Res |
Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada
|
|
EP3999539A1
(en)
|
2019-07-15 |
2022-05-25 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
|
WO2021009187A1
(en)
|
2019-07-15 |
2021-01-21 |
Intervet International B.V. |
Caninized antibodies against canine ctla-4
|
|
WO2021024742A1
(ja)
*
|
2019-08-06 |
2021-02-11 |
国立大学法人筑波大学 |
細胞傷害アッセイ方法
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
EP4031531A1
(en)
|
2019-09-17 |
2022-07-27 |
Bial-R&D Investments, S.A. |
Substituted imidazole carboxamides and their use in the treatment of medical disorders
|
|
JP2022548747A
(ja)
|
2019-09-17 |
2022-11-21 |
バイアル－アールアンドディー インベストメンツ ソシエダッド アノニマ |
酸性セラミダーゼ阻害剤としての置換されたｎ－複素環式カルボキサミド及び医薬としてのその使用
|
|
CA3150906A1
(en)
|
2019-09-17 |
2021-03-25 |
Renato T. Skerlj |
Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
|
|
BR112022004831A2
(pt)
|
2019-09-19 |
2022-06-07 |
Bristol Myers Squibb Co |
Anticorpos que se ligam a vista em ph ácido
|
|
BR112022004316A2
(pt)
|
2019-09-22 |
2022-06-21 |
Bristol Myers Squibb Co |
Caracterização espacial quantitativa para terapia de antagonista lag-3
|
|
CA3151747A1
(en)
|
2019-09-23 |
2021-04-01 |
James J. MOON |
Compositions and methods for increasing the efficacy of immunotherapies and vaccines
|
|
CA3151078A1
(en)
|
2019-09-25 |
2021-04-01 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
WO2021067863A2
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
US20220363776A1
(en)
|
2019-10-04 |
2022-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US20240190961A1
(en)
|
2019-10-25 |
2024-06-13 |
Daiichi Sankyo Company, Limited |
Combination of anti-garp antibody and immunomodulator
|
|
WO2021087458A2
(en)
|
2019-11-02 |
2021-05-06 |
Board Of Regents, The University Of Texas System |
Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
BR112022008191A2
(pt)
|
2019-11-08 |
2022-07-12 |
Bristol Myers Squibb Co |
Terapia com antagonista de lag-3 para melanoma
|
|
MX2022006213A
(es)
|
2019-11-22 |
2022-06-22 |
Theravance Biopharma R&D Ip Llc |
Piridinas sustituidas y metodos de uso.
|
|
EP4066852A4
(en)
|
2019-11-27 |
2024-05-22 |
NEC Corporation |
PHARMACEUTICAL COMPOSITION
|
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
|
JP2023510108A
(ja)
|
2019-12-19 |
2023-03-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ
|
|
MY202559A
(en)
|
2019-12-27 |
2024-05-08 |
Chugai Pharmaceutical Co Ltd |
Anti-ctla-4 antibody and use thereof
|
|
JP2023509516A
(ja)
|
2020-01-07 |
2023-03-08 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
|
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
CN115397848A
(zh)
|
2020-02-05 |
2022-11-25 |
拉利玛生物医药公司 |
Tat肽结合蛋白及其用途
|
|
EP4100426A1
(en)
|
2020-02-06 |
2022-12-14 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CA3168337A1
(en)
|
2020-02-17 |
2021-08-26 |
Marie-Andree Forget |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
|
WO2021170750A1
(en)
|
2020-02-28 |
2021-09-02 |
Orega Biotech |
Combination therapies based on ctla4 and il-17b inhibitors
|
|
KR20220150353A
(ko)
|
2020-03-05 |
2022-11-10 |
네오티엑스 테라퓨틱스 엘티디. |
면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
|
|
KR20220151189A
(ko)
|
2020-03-09 |
2022-11-14 |
브리스톨-마이어스 스큅 컴퍼니 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CN115443269A
(zh)
|
2020-03-31 |
2022-12-06 |
施万生物制药研发Ip有限责任公司 |
经取代的嘧啶和使用方法
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
|
EP4139289A1
(en)
|
2020-04-21 |
2023-03-01 |
University of Rochester |
Inhibitors of human epididymus protein 4
|
|
EP4139440A1
(en)
|
2020-04-22 |
2023-03-01 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
AU2021270458A1
(en)
|
2020-05-13 |
2022-11-10 |
AbbVie Deutschland GmbH & Co. KG |
Anti-hemojuvelin (HJV) antibodies for treating myelofibrosis
|
|
TW202200622A
(zh)
|
2020-05-13 |
2022-01-01 |
瑞士商天演藥業公司 |
用於治療癌症之組成物及方法
|
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
CA3178726A1
(en)
|
2020-05-21 |
2021-11-25 |
Gregory LIZEE |
T cell receptors with vgll1 specificity and uses thereof
|
|
WO2021247836A1
(en)
|
2020-06-03 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Methods for targeting shp-2 to overcome resistance
|
|
WO2021245071A1
(en)
|
2020-06-03 |
2021-12-09 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022003568A1
(en)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Use of leukemia-derived cells in ovarian cancer vaccines
|
|
WO2022003156A1
(en)
|
2020-07-02 |
2022-01-06 |
Oncurious Nv |
Ccr8 non-blocking binders
|
|
WO2022010847A1
(en)
|
2020-07-07 |
2022-01-13 |
Cancure, Llc |
Mic antibodies and binding agents and methods of using the same
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
CA3189336A1
(en)
|
2020-07-24 |
2022-01-27 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
|
US20230295146A1
(en)
|
2020-07-24 |
2023-09-21 |
The University Of Rochester |
Inhibitors of interleukin-1 receptor-associated kinases 1 and 4
|
|
CA3188349A1
(en)
|
2020-08-04 |
2022-02-10 |
A. Scott Muerhoff |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
|
CN112359052B
(zh)
*
|
2020-08-20 |
2023-01-03 |
山东兴瑞生物科技有限公司 |
抗EpCAM嵌合抗原受体的编码基因、制备方法、具有该基因的质粒、免疫细胞及其应用
|
|
WO2022047189A1
(en)
|
2020-08-28 |
2022-03-03 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for hepatocellular carcinoma
|
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
AU2021377699A1
(en)
|
2020-11-13 |
2023-06-15 |
Catamaran Bio, Inc. |
Genetically modified natural killer cells and methods of use thereof
|
|
WO2022115611A1
(en)
|
2020-11-25 |
2022-06-02 |
Catamaran Bio, Inc. |
Cellular therapeutics engineered with signal modulators and methods of use thereof
|
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
PH12023500013A1
(en)
|
2020-12-04 |
2024-03-11 |
Tidal Therapeutics Inc |
Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
|
|
EP4259658A4
(en)
*
|
2020-12-10 |
2024-12-04 |
Wuxi Biologics Ireland Limited |
An antibody against p-cadherin and uses thereof
|
|
WO2022130206A1
(en)
|
2020-12-16 |
2022-06-23 |
Pfizer Inc. |
TGFβr1 INHIBITOR COMBINATION THERAPIES
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
EP4267621A1
(en)
|
2020-12-24 |
2023-11-01 |
Vib Vzw |
Murine cross-reactive human ccr8 binders
|
|
US20240076391A1
(en)
|
2020-12-24 |
2024-03-07 |
Oncurious Nv |
Human ccr8 binders
|
|
WO2022136649A1
(en)
|
2020-12-24 |
2022-06-30 |
Oncurious Nv |
Non-blocking human ccr8 binders
|
|
US20220233689A1
(en)
|
2020-12-28 |
2022-07-28 |
Bristol-Myers Squibb Company |
Methods of treating tumors
|
|
SI4267105T1
(sl)
|
2020-12-28 |
2025-07-31 |
Bristol-Myers Squibb Company |
Sestave protiteles in načini njihove uporabe
|
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
|
CN117529338A
(zh)
|
2021-01-19 |
2024-02-06 |
威廉马歇莱思大学 |
多肽的骨特异性递送
|
|
WO2022157715A1
(en)
|
2021-01-22 |
2022-07-28 |
Dcprime B.V. |
Methods of tumor vaccination
|
|
AU2022212123A1
(en)
|
2021-01-29 |
2023-09-07 |
Board Of Regents, The University Of Texas System |
Methods of treating cancer with kinase inhibitors
|
|
JP2024510989A
(ja)
|
2021-03-12 |
2024-03-12 |
メンドゥス・ベスローテン・フェンノートシャップ |
ワクチン接種方法及びｃｄ４７遮断薬の使用
|
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4070799A1
(en)
|
2021-04-08 |
2022-10-12 |
Nuvamid SA |
Compositions for the improvement of sport performance
|
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
|
EP4326321A1
(en)
|
2021-04-20 |
2024-02-28 |
Institut Curie |
Compositions and methods for use in immunotherapy
|
|
EP4079310A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of alpha-synucleinopathies
|
|
EP4079311A1
(en)
|
2021-04-20 |
2022-10-26 |
Nuvamid SA |
Nmn and derivatives for its use in the treatment of depression and/or anxiety in patients having a form of parkinsonism
|
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
WO2022266034A1
(en)
|
2021-06-14 |
2022-12-22 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
|
KR102690145B1
(ko)
|
2021-06-25 |
2024-07-30 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체의 사용
|
|
BR112023022992A2
(pt)
|
2021-06-25 |
2024-01-23 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4
|
|
WO2023280790A1
(en)
|
2021-07-05 |
2023-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
JP2024531910A
(ja)
|
2021-08-04 |
2024-09-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法
|
|
EP4392451A1
(en)
|
2021-08-23 |
2024-07-03 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
CN118715440A
(zh)
|
2021-08-31 |
2024-09-27 |
雅培实验室 |
诊断脑损伤的方法和系统
|
|
JP2024534849A
(ja)
|
2021-08-31 |
2024-09-26 |
アボット・ラボラトリーズ |
脳の損傷を診断する方法及びシステム
|
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
|
KR20240116708A
(ko)
|
2021-10-05 |
2024-07-30 |
사이토비아 테라퓨틱스, 엘엘씨. |
자연 살해 세포 및 이의 사용 방법
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
KR20240099161A
(ko)
|
2021-10-20 |
2024-06-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
Bcma를 표적화하는 조성물 및 이의 사용 방법
|
|
WO2023076880A1
(en)
|
2021-10-25 |
2023-05-04 |
Board Of Regents, The University Of Texas System |
Foxo1-targeted therapy for the treatment of cancer
|
|
IL309227A
(en)
|
2021-10-29 |
2024-02-01 |
Bristol Myers Squibb Co |
LAG-3 antagonist therapy for hematological cancer
|
|
EP4433096A1
(en)
|
2021-11-19 |
2024-09-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
AU2022396272A1
(en)
*
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
|
TW202332687A
(zh)
|
2021-12-23 |
2023-08-16 |
比利時商ｅＴｈｅＲＮＡ免疫治療公司 |
免疫刺激性mrna組成物及其用途
|
|
EP4469477A1
(en)
|
2022-01-26 |
2024-12-04 |
Bristol-Myers Squibb Company |
Combination therapy for hepatocellular carcinoma
|
|
CN119256227A
(zh)
|
2022-02-04 |
2025-01-03 |
雅培实验室 |
用于检测样品中泛素羧基末端水解酶l1和/或胶质纤维酸性蛋白的存在或测量其量的侧向流方法、测定和装置
|
|
AU2023226078A1
(en)
|
2022-02-25 |
2024-08-22 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma.
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
JP2025508076A
(ja)
|
2022-03-08 |
2025-03-21 |
アレンティス・セラピューティクス・アクチェンゲゼルシャフト |
Ｔ細胞の利用能を向上させるための抗クローディン－１抗体の使用
|
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
TW202400232A
(zh)
|
2022-03-16 |
2024-01-01 |
日商第一三共股份有限公司 |
多特異性分子與免疫檢查點抑制劑之組合
|
|
CN118871451A
(zh)
|
2022-03-18 |
2024-10-29 |
百时美施贵宝公司 |
分离多肽的方法
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
JP2025515324A
(ja)
|
2022-04-28 |
2025-05-14 |
エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント |
がんを処置するためのキメラ抗原受容体改変調節性ｔ細胞
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
KR20250012631A
(ko)
|
2022-05-24 |
2025-01-24 |
다이이찌 산쿄 가부시키가이샤 |
항-cdh6 항체-약물 접합체의 투약
|
|
KR20250022071A
(ko)
|
2022-06-02 |
2025-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항체 조성물 및 이의 이용 방법
|
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
|
GB202209518D0
(en)
|
2022-06-29 |
2022-08-10 |
Snipr Biome Aps |
Treating & preventing E coli infections
|
|
AU2023298134A1
(en)
|
2022-06-29 |
2024-11-28 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
|
EP4547705A1
(en)
|
2022-07-01 |
2025-05-07 |
Transgene |
Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
|
|
EP4561635A1
(en)
|
2022-07-28 |
2025-06-04 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
|
WO2024028794A1
(en)
|
2022-08-02 |
2024-02-08 |
Temple Therapeutics BV |
Methods for treating endometrial and ovarian hyperproliferative disorders
|
|
EP4583860A1
(en)
|
2022-09-06 |
2025-07-16 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
KR20250068723A
(ko)
|
2022-09-15 |
2025-05-16 |
아보트 러보러터리즈 |
경증 및 초경증 외상성 뇌 손상을 구분하기 위한 바이오마커 및 방법
|
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
|
CN120584182A
(zh)
|
2022-11-21 |
2025-09-02 |
艾欧凡斯生物治疗公司 |
肿瘤浸润淋巴细胞扩增的二维过程及其疗法
|
|
KR20250120305A
(ko)
|
2022-12-14 |
2025-08-08 |
아스텔라스 파마 유럽 비.브이. |
Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
|
|
WO2024137776A1
(en)
|
2022-12-21 |
2024-06-27 |
Bristol-Myers Squibb Company |
Combination therapy for lung cancer
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024211475A1
(en)
|
2023-04-04 |
2024-10-10 |
Abbott Laboratories |
Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
WO2024226971A1
(en)
|
2023-04-28 |
2024-10-31 |
Abbott Point Of Care Inc. |
Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
EP4484445A1
(en)
|
2023-06-26 |
2025-01-01 |
Universität zu Köln |
Hcmv neutralizing antibodies
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
WO2025050009A2
(en)
|
2023-09-01 |
2025-03-06 |
Children's Hospital Medical Center |
Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
|
|
WO2025061993A1
(en)
|
2023-09-21 |
2025-03-27 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
EP4590715A1
(en)
|
2023-09-21 |
2025-07-30 |
Domain Therapeutics |
Anti-ccr8 monoclonal antibodies and their therapeutic use
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
EP4574165A1
(en)
|
2023-12-21 |
2025-06-25 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
WO2025133175A1
(en)
|
2023-12-21 |
2025-06-26 |
Egle Therapeutics |
Immunocytokine for cancer treatment
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025174825A2
(en)
|
2024-02-12 |
2025-08-21 |
Aera Therapeutics, Inc. |
Delivery compositions
|
|
WO2025184211A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
WO2025184208A1
(en)
|
2024-02-27 |
2025-09-04 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|